NEW YORK, Dec. 7, 2016 /PRNewswire/ --
Global Pulmonary Drugs Market: Snapshot
This report on pulmonary drugs studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered within the scope of the study. This section also provides the overall information and data analysis of the global pulmonary drugs market with respect to the leading market segments based on major products, key applications, distribution channels, and geographies.
Global Pulmonary Drugs Market: Segmentation
The global pulmonary drugs market has been studied based on major drug classes, application segments, major distribution channels, and regional as well as national markets. Based on drug classes, the global market has been categorized into eight major segments: Inhaled corticosteroids (ICS), long-acting beta2-agonists (LABA), antihistamines, vasodilators, short-acting beta2-agonists (SABA), anticholinergics, combination drugs, and others. Based on application, the global market has been categorized into five segments: Asthma & COPD, allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and others. Based on distribution channels, the global market has been categorized into four key segments: hospital pharmacies, retail pharmacies, drug stores, and e-commerce.
The market for these segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all segments, considering 2015 as the base year.
Global Pulmonary Drugs Market: Scope
The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the global pulmonary drugs market and could influence the market in the near future. Market attractiveness analysis has been provided in all the sections of the report in order to explain the intensity of competition in the market across different products/applications/distribution channels/geographies. The competitive scenario among different market players is evaluated through market share analysis in the competition landscape section of the pulmonary drugs market report. The section also includes competition matrix that analyzes the competition among some of the top global players operating in the market. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global pulmonary drugs market.
Global Pulmonary Drugs Market: Geographical Outlook
Geographically, the pulmonary drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). Each regional market for pulmonary drugs market has been further categorized into major product, application, and end-user segments considered within the scope of the study. Key country (U.S., Japan, Germany, France, U.K., Australia, Canada, China, Brazil, Mexico, India, etc.) market revenues have also been provided in different regional sections within the report. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with CAGR % from 2016 to 2024 are provided for all the regions and nations considering 2015 as the base year.
Key Players Mentioned in the Report are:
The report also profiles key players operating in the pulmonary drugs market based on various attributes such as company details, SWOT analysis, strategic overview, financials, and business overview. Major players profiled in this report include AstraZeneca plc, Novartis AG, F. Hoffmann-La Roche Ltd, Bayer AG, GlaxoSmithKline plc, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Actelion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Sunovion Pharmaceuticals, Inc. and others
The global pulmonary drugs market has been segmented as follows:
Global Pulmonary Drugs Market Revenue, by Drug Class
Inhaled Corticosteroids (ICS)
Long-Acting Beta2-Agonists (LABA)
Short-Acting Beta2-Agonists (SABA)
Others (MAbs, Enzymes, Antibiotics, Antileukotrienes, etc.)
Global Pulmonary Drugs Market Revenue, by Application
Asthma & COPD
Pulmonary Arterial Hypertension
Global Pulmonary Drugs Market Revenue, by Distribution Channel
Global Pulmonary Drugs Market Revenue, by Geography
Rest of Europe
Rest of Asia Pacific
Rest of Latin America
Middle East and Africa
Rest of Middle East & Africa
Read the full report: http://www.reportlinker.com/p04430764-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pulmonary-drugs-market---global-industry-analysis-size-share-growth-trends-and-forecast-2016---2024-300375007.html